September
Gründung
Investor Relations
Welcome to Farmako
Farmako GmbH is a fast-growing company. Our declared goal is to obtain a license for the distribution of pharmaceutical cannabis in all member states of the European market. According to expert estimates, the European market for pharmaceutical cannabis will reach a volume of 55.2 billion euros in 2028.
Investor Contact
E-Mail: press@farmako.de
For Investors
Would you like to invest? Thank you for your interest in Farmako GmbH. If you have any questions regarding possible investments, please feel free to contact us at any time.
Investor Relations
Pharmaceutical cannabis in Europe
Many European countries are opening their healthcare systems to cannabinoid therapies. The legal foundations are changing rapidly. We plan to be active in every country that brings about this change.
What?
Farmako aims to become Europe’s leading pharmaceutical cannabis company in product development, research & development and distribution.
How?
We have put together a qualified team to drive research and distribution.We are developing new, high quality products for our patients, and we can offer these products at attractive prices.
Why?
It is the founders’ personal mission to research cannabis and develop suitable therapies. Cannabinoids have been excluded from pharmaceutical research for more than 80 years. It has been impossible to make any significant progress in the production and processing and in the pharmaceutical application of cannabis as a medicine. We have made it our goal to establish Farmako as a pioneer in this industry and close the research gaps.
Mitglied im
